RBI & SEBI

OneSource Specialty Pharma announces resignation of Chief Quality Officer Bernhard Thurnbauer

Originally reported by scanx.trade as: OneSource Specialty Pharma CQO Bernhard Thurnbauer resigns effective Nov 17

17 Nov 2026, 6:15 pm IST · Xecute.finance News DeskArchive edition

The crisp read

OneSource Specialty Pharma has announced the departure of its Chief Quality Officer, Bernhard Thurnbauer. His resignation takes effect on November 17. The update was reported via financial tracking platforms.

Xecute Impact Breakdown

For CAs

  • Bernhard Thurnbauer has submitted his resignation as Chief Quality Officer of OneSource Specialty Pharma.
  • The departure becomes effective on November 17.
  • Compliance officers and stakeholders should monitor subsequent corporate filings for announcements regarding a replacement.

For businesses

  • OneSource Specialty Pharma announced the resignation of its Chief Quality Officer, Bernhard Thurnbauer, effective November 17.
  • The announcement does not detail immediate succession plans or the reasons behind the departure.
  • Stakeholders and investors should keep a close watch on subsequent corporate filings for replacement announcements.

Effective November 17

Deep dive – the full story

OneSource Specialty Pharma has officially announced that its Chief Quality Officer (CQO), Bernhard Thurnbauer, has submitted his resignation. According to the disclosure, his departure from the company becomes effective on November 17. The announcement outlines the change in executive personnel without detailing immediate succession plans or the reasons behind the departure. In the pharmaceutical sector, the role of a Chief Quality Officer is critical for overseeing manufacturing standards, regulatory compliance, and quality control systems required by health authorities.

Changes in this leadership position draw attention because quality assurance directly impacts product approvals, manufacturing plant audits, and operational continuity. The transition from the outgoing officer to a successor represents a shift in top-level oversight for the firm's quality management protocols. Stakeholders, compliance officers, and investors should keep a close watch on subsequent corporate filings for announcements regarding a replacement for the Chief Quality Officer role.

Monitoring regulatory disclosures ensures that market participants remain informed about leadership continuity and compliance readiness. The bottom line is that executive changes in key quality control positions warrant careful observation by anyone tracking the operational stability of pharmaceutical entities.

Source: news.google.com

This is news/educational content, not investment advice. Xecute.finance is not SEBI-registered. Consult a qualified professional before acting.

More from the Xecute news desk

Reading the archive edition.

This story has retired from the live feed - the full text stays here permanently. The live app adds the newest desk, Ask Xecute, deadline trackers and the daily quiz.

Open this story in the Xecute app →